Sector News

GSK starts $175M plant to boost production of vaccine star Bexsero

March 22, 2017
Life sciences

Vaccines have been one of the financial bright spots for GlaxoSmithKline and Bexsero, which it picked up in its asset swap with Novartis, has had stellar sales. To boost both, GSK is building a $175 million plant in Germany so it can expand production of the meningococcal B shot.

The antigen production plant is being built in Marsburg, one of the sites GSK acquired when it traded some of its cancer operations to Novartis in exchange for most of the Swiss company’s vaccine operations. The company expects to start validation runs in the third quarter of 2020.

“With the construction of the meningococcal B plant, we are pleased to be moving production for three of the four active components of the meningococcal B vaccine to Marburg soon,” Jochen Reutter, manager of the 780,000 square-foot site, said in a statement.

To make room for the Bexsero expansion, GSK is transferring production of its diphtheria toxoid and tetanus toxoid from Marburg to its vaccine operation in Gödöllő, Hungary. It is adding a $61.5 million facility there to accommodate that work.

There were skeptics when GSK CEO Andrew Witty decided to trade off some older cancer drugs and concentrate on lower margin areas like vaccines and consumer products, but GSK has had success building on vaccines. The U.K. drugmaker recently reported that vax sales were up 14% in 2016 to about $5.73 billion, significantly outpacing growth in much larger pharma and consumer operations.

Bexsero has done particularly well, more than doubling sales in one year to about $486 million for 2016. In fact, GSK got caught off guard by its success last year, running into shortages for awhile.

A month after it got the vaccines from Novartis, it was able to end a yearlong pricing standoff Novartis had with the United Kingdom’s National Health Service to get it added to the country’s national immunization schedule for about 800,000 babies. But when parents of thousands of children missed the NHS program and showed up at private clinics to get their children vaccinated, shortages developed. GSK responded to the “unexpected global demand” and within a couple of months had boosted production of the shot.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach